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Abstract
Monoclonal antibodies (mAbs) have become important therapeutic and prophylactic agents for a number
of indications, including infectious diseases. However, due to many issues, particularly the high cost of
antibody production, mAb therapies are limited to the world’s richest populations. Furthermore, lengthy
product development programs mean only a small number of mAb products can be produced at any one
time. Engineering novel, low-cost, and simple methods of developing and delivering mAbs would be highly
advantageous, potentially expanding the utility of antibody approaches into a wider array of applications.
Here, we describe an approach to deliver human IgG neutralizing mAbs in vivo using DNA plasmidmediated antibody gene transfer. This approach, which we term DNA mAb (DMAb) delivery, generates
biologically relevant levels of mAbs after a single intramuscular injection of antibody-encoding DNA
followed by in vivo electroporation (EP). First, we developed antibody-encoding DNA plasmids that could
reproducibly deliver human mAbs to mouse serum. We show that these plasmid-encoded antibodies have
similar binding capacity and functionality to in vitro-produced purified antibodies. Then, we use a mouse
model to show that intramuscular delivery of pDVSF-3 LALA, which encodes a human anti-Dengue virus
(DENV) IgG1 neutralizing antibody modified with a mutation that abrogates Fcγ receptor binding,
produces anti-DENV antisera capable of binding to and neutralizing DENV1-3. Importantly, mice receiving
pDVSF-3 LALA, but not the unmodified pDVSF-3 WT, were protected from both virus-only disease and
antibody-enhanced lethal disease. To build upon these initial findings, we evaluated targeted genetic
approaches and alternative delivery regimens in order to increase DMAb expression in vivo. Using DMAbs
encoding human IgG1 antibodies against Borrelia burgdorferi (the causative agent of Lyme disease) as a
model, we show that specific amino acid modifications to the framework regions of antibody variable
domains confer increased in vitro and in vivo DMAb expression levels compared to the original DMAb
sequences. Of note, these modifications were found to have no detrimental effect on the antibody’s
borreliacidal activity. Lastly, we observed that pre-treatment of the DMAb injection site with hyaluronidase
resulted in a 2.4 to 6.4-fold increase in human IgG concentration levels in vivo compared to mice receiving
EP-mediated DMAb delivery only. Taken together, these data establish DNA plasmid-based antibody gene
transfer as a safe, effective means of delivering tailored, protective monoclonal antibodies to hosts.
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ABSTRACT
ENGINEERED DNA-MEDIATED ANTIBODY GENE TRANSFER FOR PROPHYLAXIS AGAINST
INFECTIOUS DISEASES

Seleeke F. Flingai
David B. Weiner

Monoclonal antibodies (mAbs) have become important therapeutic and prophylactic
agents for a number of indications, including infectious diseases. However, due to many
issues, particularly the high cost of antibody production, mAb therapies are limited to the
world’s richest populations. Furthermore, lengthy product development programs mean
only a small number of mAb products can be produced at any one time. Engineering
novel, low-cost, and simple methods of developing and delivering mAbs would be highly
advantageous, potentially expanding the utility of antibody approaches into a wider array
of applications. Here, we describe an approach to deliver human IgG neutralizing mAbs
in vivo using DNA plasmid-mediated antibody gene transfer. This approach, which we
term DNA mAb (DMAb) delivery, generates biologically relevant levels of mAbs after a
single intramuscular injection of antibody-encoding DNA followed by in vivo
electroporation (EP). First, we developed antibody-encoding DNA plasmids that could
reproducibly deliver human mAbs to mouse serum. We show that these plasmidencoded antibodies have similar binding capacity and functionality to in vitro-produced
purified antibodies. Then, we use a mouse model to show that intramuscular delivery of
pDVSF-3 LALA, which encodes a human anti-Dengue virus (DENV) IgG1 neutralizing
antibody modified with a mutation that abrogates Fcγ receptor binding, produces antiDENV antisera capable of binding to and neutralizing DENV1-3. Importantly, mice
iv

receiving pDVSF-3 LALA, but not the unmodified pDVSF-3 WT, were protected from
both virus-only disease and antibody-enhanced lethal disease. To build upon these initial
findings, we evaluated targeted genetic approaches and alternative delivery regimens in
order to increase DMAb expression in vivo. Using DMAbs encoding human IgG1
antibodies against Borrelia burgdorferi (the causative agent of Lyme disease) as a
model, we show that specific amino acid modifications to the framework regions of
antibody variable domains confer increased in vitro and in vivo DMAb expression levels
compared to the original DMAb sequences. Of note, these modifications were found to
have no detrimental effect on the antibody’s borreliacidal activity. Lastly, we observed
that pre-treatment of the DMAb injection site with hyaluronidase resulted in a 2.4 to 6.4fold increase in human IgG concentration levels in vivo compared to mice receiving EPmediated DMAb delivery only. Taken together, these data establish DNA plasmid-based
antibody gene transfer as a safe, effective means of delivering tailored, protective
monoclonal antibodies to hosts.
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CHAPTER 1 – Introduction

Humoral immunity and the basis for vaccination
The humoral immune system is one of the first lines of defense against invading
pathogens; the generation of antibodies by B lymphocytes plays a vital role in preventing
infection and protecting the host against disease. Typically, antibody responses are
generated either by exposure to an encountered pathogen or through the process of
vaccination. Indeed, antibody responses are responsible for the efficacy of almost all of
the vaccines currently in use (S. A. Plotkin, 2009).

Vaccination has had an

immeasurably positive impact on human health, resulting in the complete elimination of
smallpox (Breman & Arita, 1980) and the drastically reduced incidence of measles,
mumps, rubella, poliomyelitis, tetanus, rotavirus, and more (Moxon & Siegrist, 2011).
Modern vaccines, typically comprised of live-attenuated microorganisms, killed viral
particles, or recombinant viral proteins, elicit the production of specific antibodies that
bind

superficial

microbial

structures

on

the

target

pathogen.

Unfortunately,

immunological pressure or imprecise genome replication can cause certain pathogens to
accumulate mutations that limit the effectiveness of antibodies originally generated
against the pathogen. Typically, antibody responses generated by traditional vaccines
only target the specific antigens found in the inoculum, and are poorly able to control
similar pathogens that carry either subtle or gross changes to the antigen. As such,
many pathogens that have adapted complex immune evasion mechanisms – such as
human immunodeficiency virus, influenza, dengue, and malaria – have proven to be
difficult targets for traditional vaccination (Karlsson Hedestam et al., 2008; Man John
Law, Landi, Magee, Lorne Tyrrell, & Houghton, 2013).
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Passive immunity and the rise of monoclonal antibody therapy
While the roots of vaccination can be traced back to the 18th century Chinese
practice of variolation against smallpox (Stanley A. Plotkin, Orenstein, & Offit, 2013), it
wasn’t until the late 19th century that the development of antibody passive transfer
therapy began to take shape. In 1890, Emil von Behring and Shibasaburo Kitasato
demonstrated that naïve animals could acquire immunity against tetanus or diphtheria
after being injected with serum obtained from animals immunized with the respective
toxins (von Behring & Kitasato, 1991). This early success paved the way for what
became known as serum therapy, in which sera from immune animals or patients are
passively administered to a recipient host in order to confer immunity to a pathogen.
Serum therapy was generally effective and widely used, yet the practice was beset with
a number of issues, such as lot-to-lot variability, dosing uncertainty, and allergic
reactions (Casadevall, 1999). While there have been improvements in the passive
transfer of polyclonal antibodies over the preceding decades, especially in regards to the
purification of antibodies from serum before passive administration, the advent of
antibiotics in the 1940s ultimately reduced the usage of serum therapy (Casadevall &
Scharff, 1994). However, there are still 11 FDA-approved polyclonal antibody
preparations used in the clinic, primarily for immune compromised individuals and postexposure prophylaxis (Robbins, Schneerson, & Szu, 1996).
Cesar Milstein and Georges Köhler’s pioneering development of hybridoma
technology in 1975 greatly expanded the possibilities of specific antibody transfer
(Kohler & Milstein, 1975). This new methodology, in which splenocytes from an
immunized mouse are fused with a mouse myeloma cell line, allowed for continuous
production of monoclonal antibodies (mAbs) against the immunogen. A little over a
decade later, the FDA approved the first mAb therapy, murine-derived muromonab-CD3,
2

ushering in a new age of antibody-based therapeutics (Todd & Brogden, 1989).
However, the murine antibodies produced by hybridomas limited their clinical
effectiveness, as anti-mouse antibody immune responses in patients led to the rapid
clearance of drug from the body, causing issues with drug readministration (Wilde &
Goa, 1996). Fortunately, advances in recombinant DNA technology and antibody
discovery techniques have led to the development of chimeric, humanized, and fully
human mAbs that are less immunogenic than their murine counterparts (Lonberg, 2005;
Traggiai et al., 2004; Vaughan, Osbourn, & Tempest, 1998). As a result, there are now
over 20 FDA-approved mAb drugs on the market, with hundreds in the development
pipeline (Keizer, Huitema, Schellens, & Beijnen, 2010).
While the successes of mAb therapy have been admirable, there are a number of
issues in current production and delivery methods that limit the modality’s clinical
potential and the populations that these drugs can reach. On the production side, clinical
antibody development is prohibitively expensive: investment costs for a commercial
antibody production facility can range anywhere from $40 million to $650 million
depending on the size of the facility, among other factors (Farid, 2007). Furthermore, the
half-life of therapeutic mAbs in vivo is typically between a few days and 3-4 weeks
(Keizer et al., 2010), necessitating frequent administrations of drug to maintain effective
antibody concentrations in patients. This partially explains the exorbitant prices for mAb
therapies, which can cost cancer patients $35,000 annually for effective antibody
treatment (Farid, 2007). Additionally, traditional antibody delivery mechanisms are time
intensive for recipients and are often performed via intravenous infusions that require
trained medical personnel to administer properly (Keizer et al., 2010). For these reasons
and more, mAb therapies are generally restricted to a subset of patients who may
benefit from such treatments.
3

Antibody gene transfer for infectious diseases
An alternative to traditional passive transfer techniques is the use of vectormediated antibody gene transfer for the delivery of well-characterized mAbs. This
approach effectively directs tissues targeted by the vector to act as antibody-producing
depots such that transfected tissues in the host ectopically express the genes of a
desired mAb in vivo, resulting in the secretion of mAbs into the circulation. This
approach has been assessed with an array of viral- and non-viral vectors (Appendix,
Table A1), each with unique characteristics worth exploring.

Adenoviral-mediated antibody gene transfer
Adenovirus (Ad) vectors have a long history as gene delivery vehicles and have
been among the most commonly used viral vectors in gene therapy (Wilson, 1996). In
regards to their use in antibody gene transfer, Ad vectors are generally known for their
rapid, yet transient, expression profiles. In one study, a group C serotype 5 Ad (Ad5)
was used to deliver a murine mAb against the protective antigen (PA) component of
Bacillus anthracis, the bacteria responsible for anthrax. Mice given the Ad vector showed
serum anti-PA antibodies as early as one day after administration, eventually peaking at
7 days post-injection. Furthermore, mice were protected as quickly as 1 day after Ad
administration, with protection lasting 8 weeks before completely disappearing by six
months (De, Hackett, Crystal, & Boyer, 2008). In another study, mice were given an Ad5
vector expressing a murine version of the anti-respiratory syncytial virus (RSV) mAb
palivizumab, followed one week later by intranasal RSV challenge. Not only did mice
receiving the Ad vector show anti-RSV serum titers within 3 days, but they also had 5.4fold lower RSV titers in the lungs compared to control animals after RSV challenge
(Skaricic et al., 2008). Soon after, Ad5 served as the vector of choice to deliver an anti4

Yersinia pestis mAb to mice, of which 80% were protected when challenged 4 days postAd administration (Sofer-Podesta et al., 2009). Ad5 vectors were also used to deliver a
camelid single-domain antibody (sdAb) against the influenza hemagglutinin (HA) protein,
protecting mice when given between 24 hours and 14 days before lethal influenza
challenge (Tutykhina et al., 2013). More recently, another antibody against Bacillus
anthracis – this time a bispecific camelid mAb – was delivered by Ad5-mediated
antibody gene transfer and protected 100% of mice up to 11 days post-Ad administration
(De et al., 2008; Moayeri et al., 2016). Taken together, Ad-mediated antibody gene
transfer is rapid, but short-lived, means of delivering mAbs in vivo.
However, a major caveat to the use of Ad-based vector systems is the
widespread pre-existing anti-Ad immunity in the human population, particularly against
the widely used human Ad5 serotype; pre-existing human Ad immunity can significantly
reduce the clinical efficacy of Ad-mediated gene transfer (Fausther-Bovendo & Kobinger,
2014). Therefore, it is generally felt that alternative vector systems will be necessary for
clinically effective vector-based antibody gene transfer.

Adeno-associated virus-mediated antibody gene transfer
Much of the pioneering work in the antibody gene transfer field began with a
seminar study from Anne Lewis and colleagues, in which a recombinant adenoassociated virus serotype 2 (rAAV2) vector was used to deliver the human anti-HIV
broadly neutralizing antibody (bnAb) b12 to Rag1 immunodeficient mice via
intramuscular injection (Lewis, Chen, Montefiori, Johnson, & Clark, 2002). Using a dualpromoter system to deliver the heavy and light chain transgenes with a single vector,
mice produced serum-detectable levels of human IgG over the course of the 6-month
study that were capable of neutralizing T cell line-adapted (TCLA) and primary HIV-1
5

isolates. These studies were later extended to delivering anti-simian immunodeficiency
virus

(SIV)

antibody-like

immunoadhesins

to

rhesus

macaques

using

self-

complementary AAV1 (scAAV1) vectors, resulting in long-lasting neutralizing activity and
protection against intravenous SIV challenge (Johnson et al., 2009). A similar approach,
known as Vectored Immunoprophylaxis (VIP), has been successfully employed in
mouse models of HIV (both intravenous and mucosal challenges) (Balazs et al., 2012)
influenza (Balazs, Bloom, Hong, Rao, & Baltimore, 2013), malaria (Deal et al., 2014),
and hepatitis C (de Jong et al., 2014). Recent work also suggests that VIP is efficacious
in nonhuman primates, as AAV-mediated delivery of a simianized version of the human
anti-HIV bnAb VRC07, in combination with the immunosuppressive drug cyclosporine,
led to substantial expression of simian VRC07 antibody in rhesus macaques for nearly 4
months and protection against simian-human immunodeficiency virus (SHIV) infection
5.5 weeks after AAV injection (Saunders et al., 2015). Another study employed
intranasal delivery of a rAAV9 vector encoding an anti-influenza HA bNAb FI6 and
showed protection against lethal influenza in mice and ferrets (Limberis, Adam, et al.,
2013), showing the range of delivery methods available for effective AAV-mediated
antibody gene transfer.
In addition to prophylactic applications of AAV-mediated antibody gene transfer,
questions of antibody expression kinetics and therapeutic efficacy have also been
explored. A number of studies have compared the kinetics of AAV-mediated antibody
gene transfer to that of Ad-mediated antibody gene transfer, and the results generally
suggest that AAV delivery has slower but longer lasting expression kinetics compared to
the rapid but transient nature of Ad-mediated antibody gene transfer (De, Hackett,
Crystal, & Boyer, 2008(Skaricic et al., 2008). Regarding the therapeutic potential of this
antibody delivery platform, one interesting study looked at a murine model of HIV
6

treatment and showed that treatment of humanized mice with antiretroviral therapy
(ART) drugs, followed by AAV-mediated expression of an anti-HIV bnAb, resulted in
durable viremic control after ART was stopped (Horwitz et al., 2013). Taken together,
these results suggest that AAV-mediated antibody gene transfer is capable of slower but
durable expression of high concentrations of mAbs in a variety of animal models.
As with Ad vectors, anti-vector immunity against AAV presents many challenges
for its use as a gene delivery vehicle in humans. AAV infection is common in humans,
resulting in high seroprevalence of IgG antibodies to multiple AAV serotypes.
Additionally, most sera positive for anti-AAV antibodies were found to have some
neutralization properties (Boutin et al., 2010), which have been found to inhibit vector
transduction in animals and humans at titers as low as 1:5 (Jiang et al., 2006; Manno et
al., 2006; Scallan et al., 2006). Clinical trials have shown that prior exposure to the AAV
capsid through natural infection may generate a pool of AAV-specific memory T cells
that are reactivated upon AAV vector-mediated gene transfer (Manno et al., 2006;
Mingozzi et al., 2007) and that these T cell responses are dose-dependent (Mingozzi et
al., 2009). One study showed that AAV2 capsid-specific human T cells proliferated upon
exposure to other AAV serotypes, suggesting that simply altering AAV serotype usage
for gene transfer may not evade the anti-vector immune response (Mingozzi et al.,
2007). However, a recent clinical study demonstrated that intramuscular delivery of an
AAV1 vector expressing M-type α-1 antitrypsin was capable of long-term transgene
expression despite the presence of a CD8+ T cell response, perhaps due to the
concomitant activation of a small natural T regulatory cell population to the AAV capsid
(Mueller et al., 2013). These data collectively suggest that immunity against the AAV
vector is a major concern clinically, with manifestations of anti-vector immunity being
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dependent on multiple factors, including pre-existing immunity, vector dose, and delivery
route.

DNA plasmid-mediated antibody gene transfer
While the majority of antibody gene transfer studies have employed viral
vectored methods, notable drawbacks such as anti-vector immunity (either pre-existing
or newly developed as a result of viral vector administration) make DNA plasmidmediated antibody gene transfer an attractive alternative (Appendix, Figure A1).
Numerous preclinical and clinical studies have shown that DNA plasmid delivery does
not elicit anti-vector immunity (Klinman et al., 2000), a benefit that has often been used
to administer multiple doses of DNA vaccines without generating an immune response to
the DNA plasmid vector (Klinman et al., 2000; MacGregor, Boyer, Ciccarelli, Ginsberg, &
Weiner, 2000). Additionally, continued advancements in DNA plasmid delivery
technology have greatly improved the prospects of DNA plasmid-mediated gene delivery
in both animal and clinical settings. For example, plasmid delivery via in vivo
electroporation (EP) improves plasmid delivery by a factor of 10-1,000 fold over naked
DNA delivery alone (Sardesai & Weiner, 2011). The advantages of DNA plasmidmediated gene transfer are further buttressed by the platform’s ease of use and largescale production, relatively low costs, and strong safety profile. Despite these
advantages, DNA plasmid-mediated antibody gene transfer is a relatively underexplored
field.
Tjelle and colleagues were the first to use EP-delivered DNA plasmids for
antibody gene transfer (Tjelle et al., 2004). In this study, mice were injected
intramuscularly with DNA plasmids encoding chimeric (mouse-human) IgG3 antibodies.
When naked DNA plasmids were injected without EP, antibody levels were similar to
8

baseline levels in control mice; however, DNA plasmid injection followed by EP led to
serum-detectable levels of human IgG ranging from 50-200 ng/mL. Mice injected with
fully murine antibody-encoding plasmids followed by EP showed greater mAb serum
levels that were detectable for at least 7 months post-injection. When sheep were
injected with murine antibody-encoding plasmids, six of seven animals showed serumdetectable murine antibody levels ranging between 30-50 ng/mL for up to 4 weeks postinjection.
This initial proof-of-concept study showed that DNA plasmids could indeed be
used to deliver antibody-encoding genes intramuscularly, but it was not until 2011 that
Yamazaki et al. published the first report showing in vivo protective functionality of DNA
plasmid-mediated antibody gene transfer against an infectious disease in mice. Animals
intramuscularly injected with DNA encoding an anti-influenza HA murine mAb followed
by EP were protected against a lethal influenza dose when challenged nearly three
weeks after DNA plasmid-mediated antibody gene transfer (Yamazaki et al., 2011).
Furthermore, these murine mAbs were detectable at least 70 days post-injection,
showing the long-term expression potential of DNA plasmid vectors.
Given the dearth of studies using DNA plasmid-mediated antibody gene transfer,
we began to explore ways to optimize this delivery method. In our initial studies, mice
were given highly optimized DNA plasmids expressing Fab fragments of the human antiHIV-1 bnAb VRC01 (Muthumani et al., 2013). When delivered with EP, a single
administration of the optimized plasmid constructs resulted in the generation of Fab
molecules in mouse sera possessing gp120-binding and HIV-1 neutralizing activity
against diverse HIV-1 isolates for at least 7 days. Importantly, this delivery method
resulted in serum-detectable production of human Fab within 48 hours, suggesting that

9

DNA plasmids possess the rapidity of Ad vector-mediated antibody gene transfer without
the anti-vector immunity.

Goals of this thesis project
Monoclonal antibody therapy carries great promise, and the advent of new
antibody discovery techniques has greatly increased the array of potent neutralizing
antibodies that target a vast number of infectious diseases. Yet the existing mechanisms
for mAb delivery preclude the use of these drugs in many patient populations, either due
to high costs or insufficient health care infrastructure. Furthermore, viral vector-mediated
antibody gene transfer carries issues of vector immunogenicity, which can limit patient
populations or prohibit readministration of additional vectored antibodies. A major goal of
my thesis project was to investigate the use of highly optimized synthetic DNA plasmids
as a possible delivery vehicle for antibody gene transfer in vivo. For our initial studies,
we developed DNA mAb-encoding plasmids (DMAbs) to express neutralizing human IgG
mAbs against dengue virus. We then incorporated targeted genetic modifications to the
antibody Fc region of the anti-DENV DMAb to assess the effect of Fcγ receptor binding
on DMAb functionality in vitro and in a mouse model of severe dengue disease. Finally,
we explored methods to increase antibody production levels in vivo through targeted
antibody framework modifications of DMAb-encoded IgGs and alternative DNA delivery
regimens. Ultimately, the primary goal of this thesis project was to determine the
feasibility of DNA-plasmid mediated antibody gene transfer in vivo as an alternative to
traditional and viral vector-based antibody delivery methods.
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CHAPTER 2 – Materials and Methods

Cell lines.

Vero cells were kindly provided by Professor Robert Doms (Children’s

Hospital of Philadelphia, Department of Pathology and Laboratory Medicine) and
cultured in Medium 199 (Invitrogen) supplemented with 5% FBS and antibiotics
(Invitrogen; 100 units/mL penicillin and 100 µg/mL streptomycin). K562 cells were
purchased from ATCC and grown in Iscove’s Modified Dulbecco’s Medium (Invitrogen)
supplemented with 10% FBS and antibiotics (Invitrogen; 100 units/mL penicillin and 100
µg/mL streptomycin). HEK293T cells were purchased from ATCC and grown in
Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen) with 10% FBS and antibiotics
(Invitrogen; 100 units/mL penicillin and 100 µg/mL streptomycin).

Dengue viruses. Dengue virus types 1 (TH-S-man; ATCC VR-1586), 2 (New Guinea C;
ATCC VR-1584), 3 (Philippines/H87/1956; BEI Resources NR-80), and 4 (H241; BEI
Resources NR-86) were amplified in Vero cells cultured at 37oC in Medium 199
supplemented with 2% FBS and antibiotics (Invitrogen; 100 units/mL penicillin and 100
µg/mL streptomycin).

Antibody plasmid construction. The DNA plasmids pDVSF-3 and pDVSF-3-LALA
encode fully human IgG1 mAbs whose variable regions were derived from the antiDENV1-3 human mAb DV87.1 [Genbank accession numbers: DV87.1 VH KC294015,
DV87.1 VL KC294016]. The DNA plasmids p319-44wt and p319-44mod1 encode fully
human IgG1 mAbs whose variable regions were derived from the anti-hisOspA antibody
319-44. Each transgene consisted of the heavy and light chain genes separated by a
furin cleavage site coupled with a P2A self-processing sequence. The transgenes were
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codon and RNA optimized for expression in humans, synthesized by GenScript and
cloned into modified pVax1 mammalian expression vectors (Invitrogen) under the control
of the human cytomegalovirus immediate-early promoter.

In vitro transfection. For transfection of DMAb plasmids, 293T cells were plated at 2.5
x 105 cells/well in flat-bottom 6-well plates. The next day, a transfection mixture,
consisting of 5 µg of DMAb plasmid incubated with 20 µL of Turbofectin 8.0 transfection
reagent (OriGene) and 100 µL of DMEM, was then added to the 293T cells. After 2 days
at 37oC, supernatant was harvested from the cells and the human IgG concentration was
measured by performing an anti-human IgG ELISA.

Western blots. For protein analysis, human antibodies were purified from supernatants
of transfected cells with a Protein A antibody purification kit (Montage Antibody
Purification Kit with PROSEP-A media, Millipore). Purified antibodies were separated in
precast Bis-Tris gels (Invitrogen) under either reducing or nonreducing conditions.
Proteins were transferred to Immobilon-FL PVDF transfer membranes (Millipore).
Membranes were blocked for 1 hour in Odyssey Blocking Buffer (Li-Cor Biosciences),
incubated with a goat anti-human IgG 680RD antibody (Li-Cor Biosciences), and
washed. Protein bands were visualized on the Li-Cor Odyssey CLx.

ELISAs.
Human IgG quantification ELISA. For quantification of total human IgG, ELISA
plates were coated with 1 µg/well of goat anti-human IgG-Fc fragment antibody (Bethyl)
overnight at 4oC. Plates were blocked with 10% FBS in PBS for 1 hour at room
temperature. After washing, samples were diluted in 1% FBS in PBS-T, added to the
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plate, and incubated for 1 hour at room temperature. Plates were washed, and HRPconjugated goat anti-human kappa light chain (Bethyl) was added for 1 hour at room
temperature. Sample was detected with SIGMAFAST OPD (Sigma-Aldrich). A standard
curve was generated using purified human IgG/Kappa (Bethyl).
DENV E protein binding ELISA. For determination of DENV E protein binding,
ELISA plates were coated with 1 µg/mL of recombinant E protein from DENV1-4
(Fitzgerald Industries International) overnight at 4oC. Plates were blocked with 10% FBS
in PBS for 1 hour at room temperature. After washing, samples were diluted in 1% FBS
in PBS-T, added to the plate, and incubated for 1 hour at room temperature. Plates were
washed, and HRP-conjugated goat anti-human IgG-Fc fragment antibody (Bethyl) was
added for 1 hour at room temperature. Sample was detected with SIGMAFAST OPD
(Sigma-Aldrich).
B. burgdorferi hisOspA binding ELISA. For determination of antibody binding
to his-tagged OspA protein (hisOspA), ELISA plates were coated with 1 µg/mL of
recombinant hisOspA protein from B. burgdorferi (courtesy of MassBiologics) overnight
at 4oC. Plates were blocked with 10% FBS in PBS for 1 hour at room temperature. After
washing, samples were diluted in 1% FBS in PBS-T, added to the plate, and incubated
for 1 hour at room temperature. Plates were washed, and HRP-conjugated goat antihuman IgG-Fc fragment antibody (Bethyl) was added for 1 hour at room temperature.
Samples were detected with SIGMAFAST OPD (Sigma-Aldrich).

Flow Cytometry.
DENV titration assay. FACS infectious units (IU)/mL were quantified by a flow
cytometry-based viral titration assay. Briefly, Vero cell monolayers were infected with
serial dilutions of DENV for 24 hours, after which infected cells positive for intracellular
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expression of the dengue E protein were enumerated by intracellular staining with the
monoclonal antibody 4G2.
Intracellular staining of DENV-infected cells. Vero cells were infected with
DENV1 TH-Sman (ATCC VR-1586), DENV2 New Guinea C (ATCC VR-1584), DENV3
H87 (BEI Resources) or DENV4 H241 (BEI Resources) at an MOI of 0.01. After 5 days,
cells were harvested, then were fixed, permeabilized, and washed with Cytofix/Cytoperm
and Cytoperm/Cytowash (BD Biosciences). Cells were incubated with sample containing
human anti-DENV antibodies diluted in Cytoperm/Cytowash for 1 hour on ice, washed,
and then stained with goat anti-human IgG Fc FITC (Abcam) for 1 hour on ice. After
washing, cells were analyzed on a LSRII (BD Biosciences).
DENV neutralization assay. Vero cells were seeded in 100 µL of Medium 199
supplemented with 5% FBS and 1% PenStrep (Invitrogen) and plated at 5 x 103
cells/well in flat-bottom 96-well plates. The next day, different dilutions of mAb-containing
sample were incubated with 200 pfu/well of DENV for 1 hour at 37oC. The neutralization
mixture was then added to Vero cells. After 3 days, cells were harvested, then were
fixed, permeabilized, and washed with Cytofix/Cytoperm and Cytoperm/Cytowash (BD
Biosciences). Cells were stained with 4G2 diluted in Cytoperm/Cytowash for 1 hour on
ice, washed, and then stained with goat anti-mouse IgG Fc FITC (Abcam) for 1 hour on
ice. After washing, cells were analyzed on a LSRII (BD Biosciences).
DENV

antibody

enhancement

assay.

To

assess

antibody-dependent

enhancement, K562 cells were seeded in Iscove’s Modified Dulbecco’s Medium (IMDM)
supplemented with 10% FBS at 5 x 103 cells/well in flat-bottom 96-well plates and
incubated with neutralization mixture formulated as above. After 3 days, cells were fixed,
permeabilized, and washed as above. Cells were stained with 4G2, washed, and then
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stained with goat anti-mouse IgG Fc FITC before a final series of washes. Cells were
then analyzed on a LSRII as above.

Animals. Wild type 129/Sv and C3H/HeNCrl mice were purchased from Charles River
Laboratories. 129/Sv mice lacking both the IFN-α/β and γ receptors (AG129) were bred
and housed at the La Jolla Institute for Allergy and Immunology (LIAI) Animal Facility.
B6.Cg-Foxn1nu/J and C57BL/6 mice were purchased from The Jackson Laboratory. All
animal housing and experimentation were approved by and conducted in accordance
with the guidelines set by the NIH and the Perelman School of Medicine at the University
of Pennsylvania or La Jolla Institute for Allergy and Immunology Institutional Animal
Care and Use Committees.

DMAb injection strategies.
DENV DMAb studies. Mice were administered a single 50 µL intramuscular (IM)
injection of plasmid into the quadriceps followed by in vivo electroporation (EP) using a
CELLECTRA adaptive constant current electroporation device (Inovio Pharmaceuticals
Inc.) as previously described (Flingai et al., 2015). Serum samples were collected preinjection and at various times after plasmid administration to determine human IgG
antibody concentration, binding ability, and neutralization capacity.
Lyme DMAb studies.

Mice were administered 30 µL intramuscular (IM)

injections of DMAb plasmid into either the quadriceps muscle or the tibialis anterior (TA)
muscle followed by in vivo electroporation unless stated otherwise. Serum samples were
collected pre-injection and at various times after plasmid administration to determine
human IgG antibody concentration and binding ability.
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Hyaluronidase pre-treatment. For hyaluronidase pre-treatment of mouse muscle,
bovine hyaluronidase (Sigma-Aldrich) at a concentration of 0.4 U/µL in deionized water
(dH2O) was injected in a volume of 30 µL into either the TA or quadriceps muscle of
anesthetized mice 30 minutes prior to DMAb injection and in vivo electroporation. A
CELLECTRA adaptive constant current electroporation device (Inovio Pharmaceuticals
Inc.) was used, as previously described(Flingai et al., 2015).

DENV challenge. All DENV challenge experiments were performed five days after DNA
administration in AG129 mice. For DENV2 virus-only challenge experiments, 5 to 6
week-old AG129 mice were infected intravenously (via the tail vein) with 1x109 genome
equivalents (GE) of DENV2 strain S221 diluted in a total volume of 200 µL PBS with
10% FCS. For DENV2 enhanced disease challenge experiments, AG129 mice were
administered 5 µg of the non-neutralizing anti-DENV mAb 2H2 intraperitoneally 30
minutes prior to infection with an intravenous 1x109 GE dose of DENV2 strain S221.

Statistical analyses. All graphs were prepared using GraphPad Prism 6 (GraphPad
Software). Survival data were expressed using Kaplan-Meier survival curves. A two-way
ANOVA

test

was

used

to

determine
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differences

between

multiple

groups.

CHAPTER 3 – Protection against dengue disease by DNA plasmid-mediated antibody
gene transfer

*The majority of the results described in this chapter have been published in: Flingai S,
Plummer EM, Patel A, Shresta S, Mendoza JM, Broderick KE, Sardesai NY, Muthumani
K, Weiner DB. (2015). Protection against dengue disease by synthetic nucleic acid
antibody prophylaxis/immunotherapy. Sci Rep 5: 12616.
INTRODUCTION
Dengue virus (DENV) is the most important mosquito-borne viral infection in
humans. In recent years, the number of cases and outbreaks has dramatically increased
worldwide. While vaccines are being developed, none are currently available that
provide balanced protection against all DENV serotypes. Advances in human antibody
isolation have uncovered DENV neutralizing antibodies (nAbs) that are capable of
preventing infection from multiple serotypes. Yet delivering monoclonal antibodies using
conventional methods is impractical due to high costs. Engineering novel methods of
delivering monoclonal antibodies could tip the scale in the fight against DENV. Here we
demonstrate that simple intramuscular delivery by electroporation of synthetic DNA
plasmids engineered to express modified human nAbs against multiple DENV serotypes
confers

protection

against

DENV

disease

and

prevents

antibody-dependent

enhancement (ADE) of disease in mice. This synthetic nucleic acid antibody
prophylaxis/immunotherapy approach may have important applications in the fight
against infectious disease.
Nearly 400 million dengue infections occur each year (Bhatt et al., 2013), and
cases of dengue fever (DF) and the potentially fatal dengue hemorrhagic fever/dengue
shock syndrome (DHF/DSS) have grown in recent decades. The geographical reach of
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dengue has expanded to include over 100 countries, resulting in a significant health and
economic burden worldwide (Bhatt et al., 2013; Gubler, 2012). While primary DENV
infection is thought to elicit persistent and effective immunity against reinfection with the
same serotype, only short-term protection is elicited against other DENV serotypes
(Rothman, 2004). Disease severity is associated with subsequent heterotypic infection,
during which non- or sub-neutralizing levels of cross-reactive antibodies from prior
infection form immune complexes with DENV that lead to increased infection of Fcγ
receptor (FcγR)-bearing monocytes and macrophages (Halstead, 1979; Peiris, Gordon,
Unkeless, & Porterfield, 1981; Peiris & Porterfield, 1979). This phenomenon, known as
antibody-dependent enhancement (ADE), gives rise to one of the greatest challenges in
developing a dengue vaccine: eliciting balanced, neutralizing immunity across multiple
serotypes while minimizing the risk of ADE. A recent live-attenuated, quadrivalent
vaccine candidate from Sanofi has shown promising protective efficacy against DENV1,
3, and 4, but underwhelming protection against DENV2 (Capeding et al., 2014;
Sabchareon et al., 2012; Villar et al., 2014), a serotype frequently associated with severe
disease from secondary infections (Leitmeyer et al., 1999). Furthermore, whether
vaccine-induced humoral responses can overcome the threat of ADE in vaccinees over
time remains to be seen.
Passive immunization studies have shown that neutralizing monoclonal or
polyclonal antibodies can provide cross-serotype protection against DENV infection in
mice (Beltramello et al., 2010; Kaufman, Summers, Dubois, & Eckels, 1987; Kyle,
Balsitis, Zhang, Beatty, & Harris, 2008; Lai et al., 2007; Shrestha et al., 2010; SukupolviPetty et al., 2010) and non-human primates (NHPs) (Lai et al., 2007). Yet monoclonal
antibody delivery in humans is incredibly expensive, creating cost-prohibitive barriers for
most regions of the world where such therapy would be needed. Developing new
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methods for delivering cross-reactive, neutralizing monoclonal antibodies into the
circulation may provide rapid, complete protection against DENV-associated disease.
One such approach involves vector-mediated gene transfer of monoclonal
antibodies. Several studies have demonstrated the effectiveness of this delivery strategy
in protecting NHPs against SIV (Johnson et al., 2009), humanized mice against HIV
(Balazs et al., 2012; Balazs et al., 2014), and mice and ferrets against influenza (Balazs
et al., 2013; Limberis, Adam, et al., 2013; Limberis, Racine, et al., 2013). While these
studies have employed intramuscular or intranasal administration of adeno-associated
virus (AAV) vectors to produce protective antibodies, our interest in DNA plasmids has
led us to explore whether such vectors can be used to deliver neutralizing monoclonal
antibodies into the circulation. DNA plasmids represent an interesting vector model for
gene transfer: they have an excellent safety profile, and unlike viral vectors, have no
vector-associated serology, allowing for repeat delivery (Klinman et al., 2000; Kutzler &
Weiner, 2008; MacGregor et al., 2000). As a proof of concept, we previously constructed
optimized DNA plasmids capable of expressing Fab fragments of the HIV-1 broadly
neutralizing antibody VRC01 in mice after intramuscular injection and in vivo
electroporation (EP), resulting in mouse sera that neutralized multiple strains of HIV-1
(Muthumani et al., 2013). To date, however, no vector system has been used to deliver
neutralizing, protective anti-DENV IgG antibodies into any animal model.
Here, we describe an approach to delivering cross-reactive neutralizing
antibodies against DENV into the circulation using DNA plasmid-mediated antibody gene
transfer. This synthetic DNA-encoded antibody approach (DMAb) produces biologically
relevant levels of mAbs after a single intramuscular injection of antibody-encoding DNA.
As this approach allows for genetic tailoring of the exact features of the desired antibody,
we further studied the role of Fc region modifications on protection.
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We demonstrate

that intramuscular delivery of a DNA plasmid encoding an anti-DENV human IgG1 nAb,
with an Fc region mutation that abrogates FcγR binding, protects mice from both virusonly infection and antibody-enhanced lethal infection.

RESULTS
DMAb optimization and in vitro characterization. The expression of human
IgG antibodies from DNA-based vectors has briefly been explored in the past (Tjelle et
al., 2004) and resulted in low levels of serum-detectable antibodies in vivo. However,
subsequent genetic optimizations to DNA plasmids and accompanying delivery systems,
particularly EP, have resulted in increased expression of desired proteins (Sardesai &
Weiner, 2011). With this in mind, we systematically optimized DMAb DNA through the
creation of two- and single-plasmid antibody-encoding DNA cassettes, with the aim of
increasing human IgG production from DMAb in vivo (Figure 1). The two-plasmid DMAb
system consisted of two plasmids encoding either the heavy chain or light chain gene
sequence of a human IgG mAb, each plasmid driven by the CMV promoter. Meanwhile,
the single plasmid DMAb system is comprised of the heavy and light chain gene
sequences of a human IgG mAb separated by a furin cleavage site and a P2A selfprocessing peptide (Figure 2), cloned into an expression plasmid driven by the CMV
promoter. For our initial human IgG characterization studies, we assessed two-plasmid
DMAb delivery in vivo, building upon the foundation laid by our previously published antiHIV-1 VRC01 human Fab two-plasmid delivery work (Muthumani et al., 2013). Dosage
studies of two-plasmid DMAb delivery in C57BL/6 mice showed a dose-dependent
increase in human IgG concentration in the serum; detectable human IgG levels were
observed as quickly as two days post-injection in mice receiving 100µg of total DNA
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(Figure 3). In order to compare two- and single-plasmid DMAb constructs, we moved to
an in vitro expression system for a more high-throughput comparison of plasmid
designs. We transfected the two- or single-plasmid DMAb plasmids into human
embryonic kidney (HEK) 293T cells, and secreted antibody levels in the supernatant
were quantified after 48 hours by ELISA. We observed a slight increase in human IgG
production from the single-plasmid condition (Figure 4), which led us to use the single
plasmid DMAb design for all subsequent experiments.
We designed and constructed two highly optimized single plasmid DMAbs
against DENV: pDVSF-3 WT, which encodes for the human IgG1 mAb DV87.1, a wellcharacterized mAb capable of neutralizing DENV1-3 (Beltramello et al., 2010); and
pDVSF-3 LALA, which encodes for an Fc region-modified version of DV87.1 with
abrogated FcγR binding by way of two leucine-to-alanine (LALA) mutations in the CH2
region (Hessell et al., 2007) that have been shown to eliminate antibody-dependent
enhancement14. Each transgene was genetically optimized, synthesized, and subcloned
into a modified pVax1 mammalian expression vector. In order to further optimize the
single plasmid DMAb constructs, we compared different human signal sequences fused
to the IgG heavy and light chain genes, assessing human IgG expression levels in vitro.
The use of human IgG or IgE heavy and light chain signal sequences led to comparable
pDVSF-3 WT expression in vitro, while the human growth hormone (HGH) signal
sequence showed reduced human IgG expression (Figure 5). Due to these results, the
human IgG signal sequences were used for all subsequent DMAbs.
In order to assess whether the LALA mutation had any effect on DMAb
production, we compared human IgG expression levels between pDVSF-3 WT and
pDVSF-3 LALA in vitro. Both pDVSF-3 WT and pDVSF-3 LALA resulted in 600 ng/mL of
human IgG, confirming that the LALA mutation has no effect on antibody expression
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levels in vitro (Figure 6). To confirm proper antibody assembly, DVSF-3 WT and DVSF3 LALA antibodies were collected from supernatants of transfected HEK293T cells and
separated by SDS-PAGE gel for Western blot analysis (Figure 7). The heavy and light
chain proteins were at their expected molecular weights, suggesting proper protein
cleavage and antibody assembly.
To assess the biological activity of the antibodies, we first performed a binding
ELISA assay that measures whether the antibody-containing supernatant can bind to
recombinant DENV1-3 E proteins. The supernatants of HEK293T cells that secreted
either DVSF-3 WT or DVSF-3 LALA antibodies were able to recognize DENV1-3 E
proteins, while DENV4 went unrecognized, as expected (Figure 8). Additionally, DVSF-3
WT- and DVSF-3 LALA-containing supernatants were able to stain Vero cells infected
with DENV1-3, whereas Vero cells infected with DENV4 were not stained by the
supernatants (Figure 9). To assess the capacity of the LALA mutation to eliminate Fcγ
receptor binding, we performed a binding ELISA that measured DVSF-3 WT and DVSF3 LALA Fc binding to immobilized FcγR1a, a receptor found on macrophages and
monocytes that has been known to mediate ADE (Kontny, Kurane, & Ennis, 1988).
DVSF-3 WT antibody secreted from HEK 293T cells were bound by the FcγR1a
receptor, whereas the DVSF-3 LALA antibody not bound by the receptor (Figure 10). To
evaluate whether this Fcγ receptor binding difference between the WT and LALA DMAbs
is manifested in differences in ADE capabilities, we used an ADE in vitro assay in which
DVSF-3 WT or LALA DMAbs, after incubation with dengue virions, were then incubated
with human monocytic K562 cells, which contain Fcγ receptors but are only susceptible
to DENV infection in the presence of enhancing antibodies. Importantly, K562 cells
exposed to DVSF-3 WT and virus showed substantial DENV infection, whereas cells
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exposed to DVSF-3 LALA and virus had no such infection in vitro, suggesting that
DVSF-3 WT is capable of enhancing DENV infection (Figure 11).
DMAb results in long-term expression of neutralizing DENV antibodies in
mouse serum. In order to investigate antibody production kinetics in vivo, we assessed
the duration of DNA plasmid-encoded human IgG expression in nude mice, which would
model antibody expression in an immune-accommodating host. For our initial long-term
in vivo kinetics studies, B6.Cg-Foxn1nu/J mice were injected intramuscularly with 100 µg
of a DNA plasmid encoding another human IgG1 anti-DENV antibody, DVSF-1 WT
(derived from DV82.11, a human IgG1 mAb that targets the DII fusion loop of the E
protein and has been well characterized for its ability to neutralize DENV1-4 (Beltramello
et al., 2010)), followed immediately by EP. Human IgG concentrations in the serum were
detectable within 5 days of injection, with peak levels of ~1000ng/mL at two weeks postinjection (Figure 12). Duration of human IgG expression lasted at least 19 weeks,
showcasing the sustained expression levels attainable with DNA plasmids. Given that
the mouse DENV challenge model uses mice from the 129/Sv background, we sought to
determine whether the antibody-encoding DNA plasmid constructs could produce
serum-detectable levels of DVSF-3 WT or LALA in this background strain. Upon
comparing DVSF-3 LALA expression levels in various immune competent and
immunodeficient mouse strains, we found that 129/Sv DMAb expression of DVSF-3
LALA was comparable to expression in B6.Cg-Foxn1nu/J immunodeficient mice at Day
7 post-injection (Figure 13). Interestingly, there was variability across different immune
competent and immunodeficient mouse strains, suggesting that DMAb expression levels
are not simply a function of the DMAb plasmid itself, nor a function of immune
competence vs. immunodeficiency. As we observed in vitro, serum from 129/Sv mice
receiving either pDVSF-3 WT or pDVSF-3 LALA showed comparable human IgG levels
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(Figure 14) and stained Vero cells infected with DENV1-3 (Figure 15). Additionally,
whereas naïve sera were unable to neutralize virus in a neutralization assay, both WT
and LALA-containing serum were capable of neutralizing DENV1-3 (Figure 16).
Dengue DMAb delivery of DVSF-3 LALA protects against enhanced dengue
disease in mice. To assess whether mice expressing DNA plasmid-encoded anti-DENV
neutralizing mAbs would be protected from DENV challenge, we employed the AG129
mouse model, which lacks type I and type II interferon (IFN) receptors and, upon DENV
infection, recapitulates many aspects of human disease (Shresta, Sharar, Prigozhin,
Beatty, & Harris, 2006; Zellweger, Prestwood, & Shresta, 2010). Importantly, these mice
have been shown to exhibit ADE, with low doses of serotype-specific as well as crossreactive antibodies both enhancing infection (Zellweger et al., 2010). For these studies,
mice were infected with the mouse-adapted DENV2 strain S221, which, in the presence
of sub-neutralizing amounts of the anti-DENV mAb 2H2, causes antibody-enhanced
severe disease and acute lethality (4-6 days post-infection) in AG129 mice at sublethal
doses (Zellweger et al., 2010).
For challenge studies, AG129 mice were given a single intramuscular injection of
pDVSF-3 WT or pDVSF-3 LALA followed immediately by EP. Negative controls received
a single intramuscular injection of pVax1 empty vector followed by EP. Five days later,
the mice were challenged with a sub-lethal dose (1x109 GE) of DENV2 S221 in the
presence (ADE) or absence (virus-only infection) of exogenous anti-DENV mAb 2H2.
Mice in the pDVSF-3 WT, pDVSF-3 LALA, and pVax1 cohorts had mean human IgG
concentrations of 750 ng/mL, 1139 ng/mL, and undetectable levels, respectively, one
day before challenge (Figure 17; p ≤ 0.0930 for comparison between pDVSF-3 WT and
pDVSF-3 LALA). Under virus-only infection conditions, we expect pDVSF-3 WT-treated
mice to experience ADE and acute lethality, as immune complexes formed by DVSF-3
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WT antibodies with DENV should lead to increased infection (Beltramello et al., 2010).
Our in vitro antibody enhancement assay results (Figures 10 and 11), which showed that
DVSF-3 WT enhances DENV infection of monocytic cells, suggests that DVSF-3 WT
has the potential to cause ADE in vivo. Conversely, we expect pVax1- and pDVSF-3
LALA-treated mice to survive, being unable to enhance disease. Indeed, five of six
pDVSF-3 LALA-treated mice and all five pVax1 mice showed no lethal disease
enhancement; all pDVSF-3 WT-treated mice succumbed to disease by day 5 (Figure 18;
p ≤ 0.0084 for comparison between pDVSF-3 LALA and pDVSF-3 WT), demonstrating
the non-enhancing functionality of pDVSF-3 LALA against virus-only infection. Under
ADE conditions, we expect both pDVSF-3 WT- and pVax1-treated mice to experience
acute lethality due to enhanced infection, whereas pDVSF-3 LALA-treated mice should
be protected from severe disease. All five mice receiving pDVSF-3 LALA survived under
ADE conditions, while those receiving either pDVSF-3 WT or pVax1 empty vector
succumbed to acute, antibody-enhanced disease within 4-5 days (Figure 19; p ≤ 0.0072
for comparison between pDVSF-3 LALA and pDVSF-3 WT). Taken together, these data
show that injection of pDVSF-3 LALA does not cause lethal enhancement after virusonly infection and protects against severe disease in ADE conditions, supporting the
concept of muscle correctly processing and expressing functional antibodies from this
platform.
DMAb delivery of multiple antibodies increases human IgG concentration
and breadth of viral coverage in mice. Given that DENV serotypes have been shown
to escape neutralization (Sukupolvi-Petty et al., 2010), it is likely that an antibody cocktail
targeting multiple epitopes on the DENV virion would produce an ideal prophylactic
strategy. DNA plasmids have been shown in numerous experiments to be delivered in
multi-plasmid formulations (Moore, Kong, Chakrabarti, & Nabel, 2002; Villarreal et al.,
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2014), suggesting that delivery of multiple antibody-encoding plasmids is feasible. To
test this concept, we injected 129/Sv mice with multiple anti-DENV DMAbs in a multi-site
injection regimen (Figure 20). Mice received a 100 µg intramuscular injection of pDVSF1 LALA, pDVSF-2 LALA (derived from DV22.3, a human IgG1 mAb that targets DI/DII of
the E protein and has been well characterized for its ability to neutralize DENV4
(Beltramello et al., 2010)), pDVSF-3 LALA, or some combination thereof. To prevent
antibody heavy and light chain recombination events, each DMAb was injected in a
different leg muscle – either the quadriceps or the TA muscle of the left or right leg.
Whereas mice injected with pDVSF-3 LALA were only capable of seroconverting against
DENV1-3, mice injected with both pDVSF-2 LALA and pDVSF-3 LALA at different sites
were able to seroconvert to all four serotypes, and mice injected with all three antibodies
had even greater binding against all four serotypes (Figures 21 and 22). These data
suggest that delivery of DMAbs can ultimately increase breadth of protection against
infectious diseases.

DISCUSSION
The rising global health burden of dengue has created an enhanced urgency to
develop a safe, inexpensive, and effective DENV vaccine that prevents both initial
infection and ADE-induced severe disease. Here, a single intramuscular injection of a
DNA plasmid encoding a modified human anti-DENV1-3 neutralizing antibody was
capable of protecting mice against antibody-enhanced DENV disease without enhancing
virus-only infection. The ability of DNA plasmids to encode protective Fc region-modified
LALA antibodies is significant due to the inability of our immune system to produce ADEpreventing antibody variants upon DENV vaccination or natural infection. Since current
vaccine candidates generate traditional antibodies, the potential of vaccines to
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inadvertently promote ADE, especially as vaccine protection wanes, is a serious
concern. Delivering Fc region-modified LALA antibodies by DMAb that protect against
both dengue fever and ADE-induced severe disease could be a unique alternative or
addition to traditional vaccine approaches.
The protection conferred by neutralizing anti-DENV mAbs expressed by DMAb is
very rapid, with complete survival in mice challenged less than a week after pDVSF-3
LALA administration – significantly more rapidly than vaccine-driven protection, which
can take weeks to months to reach peak efficacy levels. The rapid induction of immunity
may be advantageous to travelers, as well as the elderly or other populations who
respond poorly to vaccines. Travelers to endemic regions frequently receive a number
of intramuscular vaccinations prior to travel; as such, we could envision this approach
being included alongside normal travel immunization regimens.
We demonstrated that plasmid-encoded DVSF-3 LALA serum levels of 1 µg/mL
were protective against lethal enhanced dengue disease in mice. Previous work from
Beltramello and colleagues showed that i.p. delivery of 1 to 5 µg of purified DV87.1
antibody 24 hours prior to DENV challenge was able to protect mice from lethal
disease14; the protective levels observed in their study support our results here.
Importantly, we demonstrated the delivery of multiple DENV DMAb plasmids in mice,
which increased human IgG levels as well as the amount of serotypes targeted. This
novel strategy could be used to increase the breadth of protective coverage against not
just DENV, but also other infectious diseases. Furthermore, as monoclonal antibodies
have proven to be efficacious against specific cancers or autoimmune disorders,
employing DMAb to deliver monoclonal antibodies could be beneficial in such
therapeutic antibody treatments and allow many such therapies to reach underserved
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populations. In summary, DMAb provides a rapid, novel delivery system for biologically
relevant functional full-length monoclonal antibodies in vivo.
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Figure 1. Schematic of two-plasmid and single-plasmid antibody-encoding DNA
cassettes for human IgG expression.
The two-plasmid system (left) consists of two plasmids encoding the heavy or light chain
gene sequence of a human IgG monoclonal antibody, while the single-plasmid system
(right) expresses the heavy and light chain genes from a single open reading frame by
separating the two genes with a furin cleavage site and P2A self-processing peptide.
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Figure 2. Protein cleavage mechanisms used for single-plasmid DMAb design.
The 2A peptide sequence provides the initial location for protein cleavage, occurring cotranslationally via a “ribosomal skip” mechanism. The preceding furin cleavage site
provides not only a backup cleavage event further down the secretion pathway (in the
trans-golgi network), but also allows for the complete removal of the residual 2A peptide
from the upstream protein product.
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Figure 3. Development and optimization of two-plasmid DMAb.
(A) Schematic illustration of initial two-plasmid DMAb delivery system; human IgG
antibody heavy and light chain sequences were expressed on separate plasmids codelivered either in vitro or in vivo in a single formulation. (B) Dosage study for twoplasmid DMAb delivery of human IgG in C57B/6 mice measured by ELISA; DNA
amounts indicate total DNA injected intramuscularly followed by EP (100 µg = 50 µg IgG
heavy chain DNA + 50 µg IgG light chain DNA; n = 3 mice per group).
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Figure 4. Comparison of two-plasmid and single-plasmid DMAb constructs in
vitro.
(A) Schematic illustration of single plasmid DMAb delivery system; antibody heavy and
light chain sequences are separated by a combination of furin and 2A cleavage sites. (B)
Comparison of human IgG levels in vitro by ELISA from two-plasmid DMAb or single
plasmid DMAb (samples run in duplicate; data representative of two independent
experiments). N.D., not detectable.
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Figure 5. Comparison of human leader sequences on DMAb expression in vitro.
The human IgG1 (hIgG), human IgE (hIgE), and human growth hormone (HGH) leader
sequences were inserted into single plasmid DMAb constructs, and their effect on
human IgG expression was assessed by human IgG quantification ELISA (samples run
in duplicate; data representative of three independent experiments). N.D., not
detectable.
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Figure 6. LALA mutation has no detrimental effect on human IgG expression
levels in vitro.
ELISA quantification analysis of human IgG in supernatants of pDVSF-3 WT- or LALAtransfected 293T cells. The data displayed are the mean of triplicate values +/- standard
error of the mean (SEM) and are representative of three independent experiments.
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Figure 7. Single-plasmid DMAb construct produces human IgG heavy and light
chains.
Western blot analysis of pDVSF-3 WT-transfected 293T supernatants containing DVSF3 WT. Antibodies were purified by Protein A spin columns and separated by SDS-PAGE
under reducing (left) and non-reducing (right) conditions.
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Figure 8. Supernatants from pDVSF-3 WT and LALA transfectants show
comparable E protein binding.
ELISA binding analysis of human IgG in supernatants of pDVSF-3 WT- or LALAtransfected 293T cells against purified recombinant DENV E proteins (samples run in
duplicate; data representative of two independent experiments).
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Figure 9. Supernatants from pDVSF-3 WT and LALA transfectants bind to DENV13 E protein in virally-infected Vero cells.
Vero cells were either uninfected (Mock) or infected by DENV1, 2, 3, or 4, then fixed,
permeabilized, and stained with supernatants of pDVSF-3 WT- or LALA-transfected
293T cells. The data displayed are representative of two independent experiments.
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Figure 10. LALA mutation eliminates antibody binding to FcγRIa.
ELISA binding analysis of supernatants of pDVSF-3 WT- or LALA-transfected 293T cells
against immobilized FcγR1a, a receptor found on macrophages and monocytes that has
been known to mediate ADE. The data displayed are representative of two independent
experiments.
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Figure 11. Supernatants from pDVSF-3 LALA do not enhance DENV infection in
vitro.
Antibody-dependent enhancement was assessed by incubating DENV1, 2, 3, or 4 with
serial dilutions of supernatants of pDVSF-3 WT- or LALA-transfected 293T cells before
addition to K562 cells. The percentage of infected cells is shown (samples run in
duplicate; data representative of two independent experiments).
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Figure 12. Human IgG concentration in immunodeficient mouse serum after single
DMAb injection.
Total serum-detectable levels of human IgG were measured by ELISA after a single
intramuscular injection of 100 µg DNA plasmid encoding the anti-DENV human IgG
antibody DVSF-1 into B6.Cg-Foxn1nu/J immunodeficient mice. Human IgG levels
between weeks 0-4 (left) and at week 19 (right; error bars display the mean of values
from five animals +/- SEM). Each line (left) or dot (right) represents an individual mouse
(n = 5 mice).
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Figure 13. DVSF-3 LALA DMAb expression differs across various immune
competent and immunodeficient mouse models.
Total serum-detectable levels of human IgG were measured by ELISA after a single
intramuscular injection of 100 µg DNA plasmid encoding DVSF-3 LALA into immune
competent (C57B/6J, Balb/c, 129/Sv) and immunodeficient (B6.Cg-Foxn1nu/J,
B6.129S7-Rag1tm1Mom/J) mice (n = 5 mice per group, data displayed are the mean +/SEM of each group’s animals and are representative of two independent experiments).
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Figure 14. DVSF-3 WT and LALA DMAbs show comparable human IgG
concentration levels in mouse serum after intramuscular injection.
Total human IgG in serum was measured by ELISA after intramuscular injection of
pDVSF-3 WT or pDVSF-3 LALA plasmids in 129/Sv mice (n = 4-5 mice per group, data
displayed are the mean +/- SEM of each group’s animals and are representative of two
independent experiments).
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Figure 15. Mice receiving pDVSF-3 WT or pDVSF-3 LALA seroconvert within one
week post-DMAb injection.
Vero cells were either uninfected (Mock) or infected by DENV1, 2, 3, or 4, then fixed,
permeabilized, and stained with 129/Sv mouse serum taken at days 0 or 7 post-DNA
injection of pDVSF-3 WT or pDVSF-3 LALA (n = 5 mice per group, data representative
of two independent experiments).
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Figure 16. Mice receiving pDVSF-3 WT or pDVSF-3 LALA show comparable serum
DENV neutralization capacity upon seroconversion.
Neutralization was assessed by incubating DENV1, 2, 3, or 4 with serial dilutions of
129/Sv mouse serum taken at day 7 post-DNA injection of either pDVSF-3 WT or
pDVSF-3 LALA (n = 5 mice per group) before addition to Vero cells. The percentage of
infected cells is shown; error bars are the mean +/- SEM of each group’s animals).
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Figure 17. Pre-challenge levels of anti-DENV human IgG levels in AG129 mice after
DMAb delivery.
Total human IgG in serum was measured by ELISA 4 days after DNA intramuscular
injection (one day before DENV2 challenge) and EP of pDVSF-3 WT, pDVSF-3 LALA, or
pVax empty vector plasmids in AG129 mice (n = 10-11 mice per group: p ≤ 0.0005 for
comparison between pDVSF-3 WT and pVax; p ≤ 0.0001 for comparison between
pDVSF-3 LALA and pVax). N.D., not detectable.
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Figure 18. Mice receiving pDVSF-3 LALA show protection against DENV2 virusonly challenge.
AG129 mice received an intramuscular injection of either pDVSF-3 WT, pDVSF-3 LALA,
or pVax empty vector five days prior to challenge with a sublethal dose of DENV2 S221
(n = 5-6 mice per group; p ≤ 0.0084 for comparison between pDVSF-3 LALA and
pDVSF-3 WT). A Kaplan-Meier survival curve is shown.
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Figure 19. Mice receiving pDVSF-3 LALA are fully protected from antibodydependent enhancement DENV2 challenge.
AG129 mice received an intramuscular injection of pDVSF-3 WT, pDVSF-3 LALA, or
pVax empty vector five days prior to administration of an enhancing dose of the nonneutralizing anti-DENV mAb 2H2. Thirty minutes later, mice were challenged with a
sublethal dose of DENV2 S221 (n = 5-6 mice per group; p ≤ 0.0072 for comparison
between pDVSF-3 LALA and pDVSF-3 WT). A Kaplan-Meier survival curve is shown.
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Figure 20. Delivery of multiple DMAbs.
129/Sv mice received a 100 µg intramuscular injection of pDVSF-1 LALA, pDVSF-2
LALA, pDVSF-3 LALA, or some combination thereof in either the quadriceps or tibialis
anterior muscles. To prevent potential antibody recombinations between various heavy
and light chains, each muscle site was injected with one DMAb.
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Figure 21. Multi-site DMAb injections of different anti-DENV DMAbs results in
elevated human IgG concentrations in mouse serum.
Total human IgG of DVSF-1 LALA, DVSF-2 LALA, DVSF-3 LALA, DVSF-2 LALA and
pDVSF-3 LALA, or DVSF-1 LALA, DVSF-2 LALA, and DVSF-3 LALA in serum was
measured by ELISA 7 days after DNA intramuscular injection and EP of 100 µg of
respective plasmids in 129/Sv mice (n = 4 mice per group; error bars represent standard
error of the mean).
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Figure 22. Mice receiving multiple anti-DENV DMAbs seroconvert and display
increased breadth of DENV binding.
Bar graph representing the breadth of 129/Sv mouse serum staining of Vero cells
infected with DENV1, 2, 3, or 4 after injection of single (pDVSF-1 LALA, pDVSF-2 LALA,
or pDVSF-3 LALA) or multiple (pDVSF-2 LALA + pDVSF-3 LALA, or pDVSF-1 LALA +
pDVSF-2 LALA + pDVSF-3 LALA) plasmids (n = 4 mice per group; data representative
of all mice from each respective group).
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CHAPTER 4 – Optimization of DMAb delivery though targeted antibody framework
modifications and hyaluronidase pre-treatment

INTRODUCTION
Lyme disease, a tick-borne zoonotic illness caused by the spirochete Borrelia
burgdorferi sensu lato (henceforth referred to as B. burgdorferi), is a major public health
concern across the Northern Hemisphere. The disease is the most common reportable
vector-borne illness in the United States, with nearly 30,000 confirmed cases in 2013
(Adams et al., 2013), and recent evidence suggests that the number of cases in Canada
and Europe is on the rise (Fulop & Poggensee, 2008; Koffi et al., 2012). Furthermore,
the geographic reach of B. burgdorferi is expanding, as spirochetes have been identified
more recently in Asia and Australia (Mayne, 2011; Stanek & Reiter, 2011).
B. burgdorferi is transmitted to humans, domestic animals, and wildlife hosts by
Ixodes ticks in the larval and nymphal stages (Anderson, 1988; Kurtenbach et al., 2006;
LoGiudice, Ostfeld, Schmidt, & Keesing, 2003). Throughout the three-stage life cycle of
the tick — larva, nymph, and adult — B. burgdorferi undergoes differential expression of
various outer surface lipoproteins (Osps), each with varying levels of homology across
B. burgdorferi isolates. OspA, expressed by spirochetes in the tick midgut, is highly
conserved in North American strains of the spirochete (Probert, Crawford, Cadiz, &
LeFebvre, 1997), and it is quite immunogenic, eliciting immune responses in numerous
Lyme disease animal models (de Silva, Telford, Brunet, Barthold, & Fikrig, 1996; Fikrig,
Barthold, Kantor, & Flavell, 1990, 1992; Probert et al., 1997). Indeed, an OspA vaccine
had an efficacy of 79% in phase III human clinical trials, leading to an FDA-approved
Lyme disease vaccine available from 1998 until 2002 (Abbott, 2006). Currently, there is
no available Lyme disease vaccine for humans (Embers & Narasimhan, 2013).
51

It has been well established that antibodies are critical mediators in protection
against Lyme disease (Fikrig, Barthold, Chen, Chang, & Flavell, 1997; McKisic &
Barthold, 2000). Passive immunization with serum from acutely infected mice (Barthold,
Feng, Bockenstedt, Fikrig, & Feen, 1997) or chronically infected humans (Fikrig et al.,
1994) has been shown to provide protection in mice against tick-mediated Lyme
challenge. Interestingly, OspA antibodies elicited by immunization with an OspA vaccine
prevent B. burgdorferi infection by binding to and killing OspA-expressing spirochetes
directly in the tick midgut, preventing migration of the bacteria to the salivary glands
before transmission to the host can occur (de Silva et al., 1996; Fikrig, Telford, et al.,
1992; Nowling & Philipp, 1999).
DNA monoclonal antibody (DMAb) delivery provides an alternative to vaccination
or passive antibody therapy for generating rapid, antibody-based immunity against
infectious diseases. DMAbs are highly optimized DNA plasmids capable of delivering
genes encoding well-characterized monoclonal antibodies (mAbs) to hosts. We have
previously described DMAb delivery in the context of HIV, generating Fab fragments of
the human broadly neutralizing antibody VRC01 in mice after intramuscular injection of
DMAb plasmids and in vivo electroporation (EP) (Muthumani et al., 2013). More recently,
DMAb delivery in mice generated long-lived full-length human IgG neutralizing
antibodies against Dengue virus that completely protected mice from virus-only and
lethal antibody-dependent enhancement Dengue challenge (Flingai et al., 2015).
However, higher DMAb expression levels may be necessary for prophylactic or
therapeutic benefits for a number of indications. As such, we investigated optimizations
that may increase DMAb-mediated antibody concentrations in vivo. Previous studies
have shown that improving antibody stability through targeted framework mutations and
grafts can increase in vitro antibody production levels without perturbing antibody
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functionality (Ewert, Honegger, & Pluckthun, 2003, 2004; Honegger, Malebranche,
Rothlisberger, & Pluckthun, 2009; Jung & Pluckthun, 1997; Knappik et al., 2000). Use of
these optimizations in vector-mediated antibody gene transfer systems has been limited,
with one study showing that minor mutations to the light chain of an influenza antibody
delivered with AAV could improve expression levels in vivo (Balazs et al., 2013).
Additionally, several studies have shown that the use of the enzyme hyaluronidase
before DNA plasmid injection significantly increased gene delivery to skeletal muscle
cells (Long et al., 2005; McMahon, Signori, Wells, Fazio, & Wells, 2001; Mennuni et al.,
2002; Molnar et al., 2004). We sought to explore the use of these approaches, as well
as altering DMAb dosing, in an effort to increase DMAb expression levels in vivo.
Here, we assess the ability of targeted framework modifications, hyaluronidase
pre-treatment of mouse muscle, and increased DMAb dosing to increase the in vivo
production of human anti-Lyme IgG antibodies. We show that these optimizations, when
used together, can increase DMAb expression levels in vivo between 2.4 to 6.4-fold
without diminishing antibody functionality and that these improvements are long lasting
in immunodeficient mice.

RESULTS
Characterization of anti-Lyme DMAbs. In collaboration with the non-profit
organization MassBiologics, we obtained the gene sequences of four anti-Lyme human
IgG antibodies with varying breadths of Borrelia neutralization capabilities, OspA
affinities, and protective efficacies in mice (Table 1). We developed DMAb vectors
expressing 319-44, 221-7, 212-55, and 857-2 by inserting the heavy and light chains of
the human IgGs into our previously described DMAb expression construct (Flingai et al.,
2015). We transfected human embryonic kidney (HEK) 293T cells with the four DMAb
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vectors or an empty pVax vector vehicle, collected the supernatant 48 hours later, and
compared human IgG expression levels in vitro. The plasmid p319-44 showed the
highest secreted human IgG production levels of all four anti-Lyme DMAbs, with the
most potent IgG, 221-7, expressing the lowest concentration of human IgG after
transfection (Figure 23). Importantly, supernatant from all four DMAb transfections
displayed binding to immobilized his-tagged OspA (hisOspA) protein.
In order to determine anti-Lyme DMAb expression levels in a relevant mouse
model, C3H/HeNCrl mice were injected in the quadriceps muscle with 100 µg of p31944, p221-7, p212-55, p857-2, or empty pVax vector vehicle. Within 48 hours, mice given
p319-44 seroconverted to hisOspA, and by 1 week post-injection, 319-44 and 857-3 IgG
levels reached 400-500 ng/mL. Serum concentrations of 212-55 and 221-7 were
drastically lower at day 7, only reaching 50-150 ng/mL in mice (Figure 24). Nonetheless,
all mice receiving anti-Lyme DMAbs seroconverted by day 7, illustrating the rapid
expression kinetics of DMAb delivery in vivo.
Framework optimization of 319-44 DMAb. Given the modest expression levels
of some anti-Lyme DMAbs, we investigated methods to increase DMAb expression in
vivo. We focused on optimizing p319-44, as this DMAb expressed a fairly potent mAb
that showed promising expression levels in mice. To improve p319-44 DMAb
expression, we further optimized both the light chain and heavy chain variable region
sequences with a targeted approach that focused on increasing antibody stability
through significant framework region modifications (Figure 25), a process that has been
shown to improve antibody production in both in vitro (Ewert et al., 2003, 2004;
Honegger et al., 2009; Jung & Pluckthun, 1997; Knappik et al., 2000) and in vivo (Balazs
et al., 2013) settings. First, we identified a high-expressing DMAb to act as an acceptor
framework for grafting. This acceptor DMAb, which has been shown to express >5
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µg/mL of human IgG in immunodeficient mice after a single dose of 100 µg DNA (data
not shown), is comprised of heavy and light chains from the highly stable germline
families hVH3 and hVκ1, respectively. To create the optimized 319-44, we grafted the
three CDRs and an additional 22 crucial heavy and light chain framework residues of
319-44 onto the high-expressing DMAb genes.
After confirming that these modifications did not alter the capacity of 319-44mod1
DMAb production of human IgG antibodies in vitro (Figure 26), we assessed whether the
optimizations would increase the production levels of 319-44 by comparing human IgG
concentration levels in 293T cell supernatants following transfection of cells with the wild
type (319-44wt) or optimized (319-44mod1) DMAb constructs (Figure 27). 319-44wt and
319-44mod1 showed comparable binding to purified hisOspA protein, yet 319-44mod1
production levels were over two-fold higher than the wild-type DMAb. To ensure that the
optimizations of 319-44mod1 did not abrogate borreliacidal capacity, we compared the
two DMAbs in an in vitro borreliacidal assay against B. burgdorferi. 319-44mod1 showed
a 11-fold increase in potency (measured as EC50) compared to 319-44wt (Figure 28).
Thus, we were able to increase DMAb expression levels and maintain wild-type
functional activity through systematic engineering of framework optimizations.
Systemic expression of 319-44 DMAbs in mice. We have demonstrated
recently that a single intramuscular administration of a DMAb encoding an anti-dengue
virus neutralizing mAb resulted in serum levels of slightly over 1 µg/mL of mAb in mice
(Flingai et al., 2015). Here, we sought to determine whether increasing DMAb dosing
and distributing this dosage across multiple muscles could lead to greater human IgG
expression levels in vivo. To assess 319-44 DMAb expression levels in mice, we
injected various doses of either 319-44wt or 319-44mod1 DMAbs into the tibialis anterior
(TA) or quadriceps muscles of C3H/HeNCrl mice, followed by EP. Administration of 100
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µg, 200 µg, or 300 µg of 319-44wt DMAb resulted in a dose-dependent increase in
antibody concentrations in serum, as mice receiving the highest dose of 319-44wt
showed an average serum concentration levels of 1.2 µg/mL one week postadministration (Figure 29). The same dose of 319-44mod1 showed an even greater
serum antibody concentration of 1.4 µg/mL one week post-administration, illustrating the
positive effect of the amino acid optimizations on antibody concentration in vivo, albeit to
a less drastic effect than seen in vitro. Using an anti-hisOspA binding ELISA, we
demonstrated that the optimized antibodies, when expressed from muscle cells in vivo,
show a slight dip in antigen binding compared to 319-44wt, but ultimately retain antigen
binding to recombinant hisOspA protein (Figure 29).
Pre-treatment with hyaluronidase significantly increases 319-44 DMAb
expression in vivo. Previous studies have demonstrated the positive effect of
hyaluronidase on gene transfer in skeletal muscle (Long et al., 2005; McMahon et al.,
2001; Mennuni et al., 2002; Molnar et al., 2004). To investigate whether DMAb
production would be improved by pre-treatment of muscle cells with hyaluronidase, we
injected C3H mice in the TA muscle, the quadriceps muscle, or both, with 0.4 U/µL of
bovine hyaluronidase in a 30 µL volume 30 minutes prior to EP-mediated DMAb
delivery. At 7 days post-injection, we measured human IgG concentration levels in
mouse sera by anti-human IgG ELISA. Mice receiving 319-44wt DMAb without EP
showed undetectable human IgG serum levels, regardless of whether the muscles were
pre-treated with hyaluronidase (data not shown). However, mice that received EPmediated

DMAb

delivery

with

hyaluronidase

pre-treatment

saw

human

IgG

concentration levels increase by between 2.4 to 6.4-fold above animals that received
EP-mediated DMAb delivery only (Figure 30). After a 300 µg dose of EP-mediated
DMAb delivery with hyaluronidase pre-treatment in mice, the average human IgG serum
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concentration of 319-44wt IgG peaked at 5.7 µg/mL, while 319-44mod1 IgG peaked at
an average of 6.7 µg/mL.
To assess the effect of hyaluronidase pre-treatment on long-term DMAb
expression kinetics, immunodeficient Foxn1nu/J mice received 300 µg of 319-44mod1
DMAb delivered with EP with or without hyaluronidase pre-treatment. Not only did
hyaluronidase pre-treatment lead to increased 319-44mod1 expression levels by day 7
post-injection, but the increase in serum human IgG concentration was sustained over
the course of 4 weeks, peaking at 5 µg/mL 14 days after DMAb administration (Figure
31).

DISCUSSION
There are many advantages to the use of DNA plasmid as a tool for antibody
gene transfer. The simplicity of use, the lack of anti-vector immunity, the excellent safety
profile, and the relatively inexpensive production costs compared to viral vectors make
DNA plasmid-mediated antibody gene transfer an attractive alternative to viral vector
approaches. However, one disadvantage is the relatively low mAb expression levels
from DMAb delivery compared to AAV- or Ad-mediated antibody gene transfer. In this
study, we explored three strategies to improve DMAb delivery in vivo: 1) antibody
framework modifications to increase mAb stability; 2) DMAb dosing; and 3) pretreatment of muscle cells with the enzyme hyaluronidase. While many of these
strategies have been employed in other DNA delivery or mAb production contexts, there
are still many questions to be answered regarding their use in DNA plasmid-mediated
antibody gene transfer.
Antibody framework modifications led to substantial increases in human IgG
production in vitro, with only moderate increases observed in vivo. This may be
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explained by the fact that these stabilizing modifications have been extensively
investigated in the context of in vitro antibody production and not in in vivo environments
inside the host’s muscle cells. Perhaps this in vivo mAb production environment
dampens the positive effects seen in vitro; it would be advantageous to determine which
framework modifications are responsible for mAb stability in vivo, and how these
stabilizing modifications affect DMAb-generated human IgG concentration levels in
serum. Further studies are needed in order to determine whether such modifications
should be a major aspect of DMAb optimization strategies going forward. Importantly, if
framework modifications are made, both antigen binding and functionality should be
evaluated. In this particular study, the protective efficacy of 319-44wt and 319-44mod1
should be compared in a tick-mediated B. burgdorferi challenge model in mice.
While DMAb dosing had a clearly positive effect on human IgG concentration
levels in mouse serum, intramuscular hyaluronidase pre-treatment amplified the effect to
a drastic degree. Indeed, mice receiving 300 µg of 319-44mod1 without hyaluronidase
had human IgG concentration levels less than mice receiving 100 µg of 319-44wt with
hyaluronidase. These results suggest that hyaluronidase could act as a dose-sparing
agent, which has the additive effect of minimizing the number of DMAb injection sites.
Alternatively, hyaluronidase pre-treatment boosted human IgG concentrations to nearly
10 µg/mL in the mice also receiving the 300 µg dose of 319-44mod1, showing the
combinatorial effect all three optimization strategies can have on DMAb expression in
vivo. Optimal hyaluronidase pre-treatment time intervals and dosing should be explored
in future studies. Taken together, this work shows a number of ways DMAb delivery can
be enhanced for increase in vivo human IgG expression.
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Table 1. Characterization of anti-Lyme purified antibodies used in study.
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Figure 23. Comparison of various anti-B. burgdorferi DMAbs in vitro.
ELISA human IgG quantification (A) and immobilized hisOspA protein binding (B)
analysis of human IgG in supernatants of HEK 293T cells transfected with either p21255, p857-3, p319-44wt, p221-7, or pVax empty plasmids. The data displayed are the
mean of duplicate values +/- standard error of the mean (SEM) and are representative of
two independent experiments.
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Figure 24. Expression of various anti-B. burgdorferi DMAbs in vivo.
Total human IgG in serum (A) or binding to immobilized hisOspA protein (B) was
measured by ELISA after intramuscular injection of p319-44wt, p857-3, p212-55, p2217, or pVax empty plasmids in C3H/HeNCrl mice (n = 5 mice per group, data displayed
are the mean +/- SEM of each group’s animals and are representative of two
independent experiments).
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Figure 25. Design of 319-44mod1 through antibody framework optimization of 31944wt.
Amino acid alignment of 319-44wt (319-44 wild type), 319-44mod1, and the human germ
line sequences (Vκ1 for light chain, VH3 for heavy chain) on which 319-44mod1
optimizations are based. 319-44mod1 amino acid residues identical to only 319-44wt
sequences (green) or the human germ line sequence (red) are shown. Amino acids
identical across all three sequences are indicated by periods. The complementaritydetermining regions (CDRs) of 319-44wt and 319-44mod1 are identical; the CDR3
region of 319-44wt and 319-44mod 1 are shown in the human germ line CDR3 region
above due to the uncertainty of the original human germ line CDR3 sequences.
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Figure 26. Design and production of 319-44mod1 DMAb.
(A) Plasmid design for single-plasmid 319-44mod1 DMAb. F, furin cleavage site; 2A,
P2A peptide cleavage site; pA, polyadenylation sequence. (B) Western blot analysis of
p319-44mod1 DMAb-transfected 293T supernatants containing 319-44mod1 human
IgG. Antibodies were purified by Protein A spin columns and separated by SDS-PAGE
under reducing (left) and non-reducing (right) conditions.
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Figure 27. 319-44mod1 exhibits increased human IgG production compared to
319-44wt in vitro.
ELISA human IgG quantification (A) and immobilized hisOspA protein binding (B)
analysis of human IgG in supernatants of HEK 293T cells transfected with either p31944wt or p319-44mod1 DMAbs. The data displayed are the mean of duplicate values +/standard error of the mean (SEM) and are representative of two independent
experiments.
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Figure 28. Framework modifications of 319-44mod1 have no detrimental effect on
antibody borreliacidal activity in vitro.
Purified 319-44wt or 319-44mod1 antibodies were evaluated with a borreliacidal assay
against B. burgdorferi bacteria (left; CDA-1 antibody = negative control); EC50 values of
purified antibodies (right).
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Figure 29. In vivo delivery of 319-44mod1 DMAb leads to slight increase in 319-44
IgG with concomitant reduction in purified hisOspA binding capacity.
Total serum-detectable levels of human IgG (A) and immobilized hisOspA protein
binding (B) were measured by ELISA after various doses of 319-44wt or 319-44mod1
DMAb were injected intramuscularly in C3H/HeNCrl mice. (n = 5 mice per group, dots
represent individual animals within a group, while bars represent mean +/- SEM of the
group).
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Figure 30. DMAb delivery with hyaluronidase pre-treatment increases 319-44 IgG
concentration in vivo.
Total serum-detectable levels of human IgG (A) and immobilized hisOspA protein
binding (B) were measured by ELISA after various doses of 319-44wt or 319-44mod1
DMAb were injected intramuscularly with or without hyaluronidase pretreatment in
C3H/HeNCrl mice. (n = 5 mice per group, dots represent individual animals within a
group, while bars represent mean +/- SEM of the group).
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Figure 31. Hyaluronidase pre-treatment before DMAb delivery leads to long-term
increase in human IgG concentration in vivo.
Total serum-detectable levels of human IgG (A) and immobilized hisOspA protein
binding (B) were measured by ELISA after a 300 µg dose of 319-44mod1 DMAb was
injected intramuscularly with or without hyaluronidase pretreatment in B6.Cg-Foxn1nu/J
immunodeficient mice. (n = 5 mice per group, data displayed are the mean +/- SEM of
each group’s animals).
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CHAPTER 5 – Discussion and Future Directions

The promise of vector-mediated antibody gene transfer has generally been
countered by the field’s predominant use of viral vectors, which time and again have
shown the pesky trait of being targeted by pre-existing anti-vector immunity, or of
eliciting an anti-vector immune response upon administration. These responses have
been known to limit the clinical efficacy of viral vector gene transfer in numerous studies
(Jiang et al., 2006; Manno et al., 2006; Scallan et al., 2006), even if animal models
generally downplay such effects. An alternative to viral vector-mediated antibody gene
transfer is DNA plasmid-mediated antibody gene transfer. Unlike viral vectors, DNA
plasmids do not elicit anti-vector immunity (Klinman et al., 2000), which allows for
repeated administrations of plasmid vectors when desired (Klinman et al., 2000;
MacGregor et al., 2000). Furthermore, the production of large stocks of DNA is relatively
inexpensive when compared to the creation of clinical grade viral vectors for gene
delivery. Despite these and many other advantages (ease of use, great safety record,
etc.), DNA plasmids have rarely been used as a tool to deliver monoclonal antibody
genes in vivo. Such a dearth of research on this topic has led our lab to investigate the
feasibility of DNA plasmid-mediated antibody gene transfer. Using the gene sequences
of well-characterized mAbs targeting two distinct pathogens – dengue virus (subject of
Chapter 3) and the B. burgdorferi bacteria responsible for Lyme disease (subject of
Chapter 4) – we outline in this thesis the development of and optimization strategies for
an effective DNA plasmid-based mAb delivery system, which we call DMAb.
This study is the first demonstration of a DNA plasmid being used to deliver fulllength human IgG antibody genes for in vivo production (Figure 3, Figure 12). After a
single intramuscular injection of a DNA plasmid cocktail encoding the heavy and light
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chains of a human IgG1 antibody on two separate plasmids, biologically active
antibodies were produced and properly assembled within muscle cells and secreted into
the circulation within 48 hours of DNA injection (Figure 3). Seeing a need to simplify
DMAb delivery and maximize the chances of the heavy and light chain genes being
transcribed within the same muscle cell, we then developed a single plasmid DMAb
vector in which the heavy and light chain genes of a mAb are separated on a single
open reading frame by two cleavage sites used extensively in nature: the 2A peptide and
a furin cleavage site (Figure 2, Figure 4). These plasmid modifications showed no
detrimental effect on human IgG expression levels in vitro, suggesting that a single
plasmid system could be feasible for further study in vivo. Indeed, our single-plasmid
anti-DENV DMAb, DVSF-3, when injected intramuscularly with EP into mice, showed
that this simplified approach could produce biologically relevant levels of human IgG in
mouse serum within 1 week of DMAb administration (Figure 13). Importantly, mice
injected with the modified DMAb pDVSF-3 LALA were completely protected from a lethal
ADE DENV2 challenge, even though the DMAb was administered only five days prior to
challenge (Figure 19). These results highlight the rapid expression kinetics of DMAbdriven ectopic human IgG expression in mice.
Similar kinetics have been observed after Ad-mediated antibody gene transfer,
yet there are two characteristics that differentiate these approaches. Firstly, Ad-mediated
antibody gene transfer in mice produces antibody expression levels above 100 µg/mL in
vivo, whereas DMAb delivery in this study leads to human IgG serum concentrations
between 500 ng/mL and 10 µg/mL in mice. However, these numbers deserve proper
context. Studies employing Ad-mediated antibody gene transfer typically use murine
mAbs, which abrogates immune responses against the transgene product in mice. In our
lab, we compared DMAb-mediated human IgG expression to DMAb-mediated murine
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IgG expression in mice and observed that DMAb-mediated murine IgG expression is
many fold greater than DMAb-mediated human IgG expression (data not shown),
suggesting that the species of the antibody plays a fundamental role in even short-term
expression kinetics in animal models. Secondly, Ad-mediated antibody gene transfer, as
with other viral vector systems, elicits anti-vector immune responses, whereas DMAb
delivery does not. These major differences frame DMAb delivery as a promising
alternative to viral vector-based antibody gene transfer that would greatly benefit from
exploring multi-DMAb delivery approaches and optimizations to improve antibody
expression levels in vivo.

Future directions: post-exposure prophylaxis or therapy
Several infectious diseases, including hepatitis A and B, rabies, and tetanus,
have established post-exposure prophylaxis (PEP) protocols that are effective at
preventing the development of disease or limiting the transmissibility of an infectious
agent after initial exposure (Bader & McKinsey, 2013). Many of these treatments use
intravenous immune globulin (IVIG) regimens alone or in combination with available
vaccines. Our data suggest that DMAb delivery in mice leads to rapid production of
human IgG, typically detectable in serum between 24 and 48 hours (Figure 3, Figure
12). Future studies should alter when DMAb is administered in relation to pathogen
challenge to assess whether DMAbs may prove beneficial as tools for PEP.
Furthermore, recent work from our lab has demonstrated the protective “immediate and
persistent” efficacy of DMAb and vaccine co-administration in the context of chikungunya
infection (Muthumani et al., 2016), suggesting that DMAb/DNA vaccine formulations
should also be studied for their ability to replicate IVIG/vaccine regimens for PEP.
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Future directions: delivery of multiple DMAbs
In Chapter 3, we used an anti-Dengue virus antibody model to explore DMAbmediated human IgG production in vivo, concluding those studies with preliminary work
on multi-DMAb delivery in a host (Figure 20, Figure 21, Figure 22). Our data suggest
that the breadth of coverage against a pathogen can be increased through multi-site,
multi-DMAb delivery, which would be a crucial need for any comprehensive antibodybased prophylactic that aims to minimize antibody escape. More studies should be
devoted to optimally delivering multiple DMAbs in a simpler fashion, keeping in mind the
dangers of antibody heavy chain-light chain protein rearrangements that may occur if
different antibodies are being expressed in the same cell.
One future goal of these studies is to develop new antibody structures that
eliminate the possibility of heavy chain-light chain protein rearrangements; such an
antibody structure would allow for multiple DMAbs to be delivered into a single site.
Alternatively, developing bispecific DMAbs could increase the breadth of antibody
targets without the need to deliver multiple DMAb plasmids. Regardless of the method
employed, clinical success of any antibody gene transfer approach will have to consider
how to minimize antibody escape, no matter how broadly neutralizing a single delivered
antibody may be. Antibody cocktail studies in mice and nonhuman primates have
worked to address issues of antibody escape to varying degrees of success, so it is in
the antibody gene transfer field’s benefit to do the same.
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Future directions: optimization strategies
In Chapter 4, we used an anti-Lyme disease antibody model to explore a threetiered optimization strategy to improve DMAb expression levels in vivo: DMAb dosing,
antibody framework modifications, and hyaluronidase pre-treatment.
DMAb dosing. Building on our previous work that suggested multiple injections of
DMAb plasmids could increase the breadth of coverage against DENV and boost total
human IgG expression levels in mouse serum (Figure 20, Figure 21, Figure 22), we
established DMAb dosing as one tier for improving DMAb expression levels in vivo. The
dosage studies outlined in Chapter 4 of this thesis show that there is a DMAb dosedependent escalation in human IgG levels in mouse serum that appears to be linear in
nature (Figure 29). Further studies need to be conducted to determine how much DMAb
plasmid can be administered per muscle site without diminishing returns.
Antibody framework modifications. Framework modifications in the realm of
antibody gene transfer is a relatively unexplored field, with the majority of studies
focusing less on improving antibody stability and more on reducing immunogenicity of
the transgene in large animal models. We sought to use well-established stabilizing
framework modifications to improve DMAb expression levels in vivo, with the assumption
that enhanced antibody stability in vitro could also enhance the longevity of antibodies in
vivo. The framework modifications of 319-44mod1 led to greatly increased in vitro mAb
production and a slight increase in in vivo mAb production, suggesting that these
modifications may be a promising avenue of exploration to improve antibody
concentrations in the circulation.
However, there is still much to understand about these framework modifications
and how they may affect antibody half-life and functionality in vivo. Future studies should
focus on two key areas of inquiry: 1) determining which antibody framework families
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(e.g. VH1 or Vκ3) are most stable in vivo, and whether this stability leads to higher
antibody peak concentrations, a more durable increase in serum concentration levels, or
both; and 2) assessing the antibody structure pre- and post-modifications to better
understand how these modifications may affect antigen binding and functionality. An
interesting observation in Chapter 4 was that 319-44mod1 appears to have reduced
antigen-binding capabilities to purified hisOspA protein compared to 319-44wt, but the
borreliacidal activity was unperturbed. Therefore, both affinity and functionality must be
investigated concomitantly in future studies.
Hyaluronidase pre-treatment. Our data suggest that hyaluronidase pre-treatment
of muscle cells can greatly enhance DMAb gene delivery and lead to increased human
IgG serum concentrations in mice. However, future studies should evaluate various
hyaluronidase pre-treatment regimens in order to optimize DMAb delivery. For example,
the interval between hyaluronidase pre-treatment and DMAb administration with EP
should be more fully explored. For studies in Chapter 4, a 30-minute interval was
sufficient for the enzyme to be absorbed in the targeted muscle area, but whether that
period of time is sufficient to maximize DMAb delivery is currently unknown. Balancing
the length of this pre-treatment interval with the positive effects on DMAb expression is a
key optimization step with relevance both in animal models and in the clinic, where one
could imagine that too long of an interval may present practical logistical issues (e.g.
extended doctor visits).
Hyaluronidase dosing is another aspect that must be optimized. Studies have
shown that hyaluronidase pre-treatment does not increase muscle damage (Long et al.,
2005; McMahon et al., 2001), but these studies have only used a single hyaluronidase
dose. Furthermore, hyaluronidase has been shown to amplify the inflammatory effects of
in vivo EP (Chiarella, De Santis, Fazio, & Signori, 2013), suggesting that future DMAb
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studies using hyaluronidase should be aware of how this inflammatory milieu may
exacerbate anti-transgene immune responses in immune competent animal models.
Optimizing hyaluronidase dosing may help balance the potentially detrimental
inflammatory response of EP + hyaluronidase with the hyaluronidase-mediated boosting
of DMAb-mediated human IgG expression levels. Therefore, hyaluronidase pretreatment requires optimizing on multiple levels, and future studies should compare
various combinations of hyaluronidase dose and pre-treatment timing to improve DMAb
delivery in vivo.

Summary and concluding thoughts.
In summary, we show that DNA plasmid-mediated antibody gene transfer is a
feasible method for delivering biologically active human IgG antibodies in vivo. DMAb
delivery of an anti-DENV neutralizing antibody was capable of completely protecting
mice from a lethal ADE DENV challenge, and optimizations to DMAb delivery via
antibody framework modifications, DMAb dosing, and hyaluronidase pre-treatment were
able to significantly increase human IgG concentrations in mouse serum. The major
focus of future studies should be on optimizing DMAb-mediated mAb cocktail delivery
while increasing antibody concentration levels in serum.
As researchers continue to refine the process of mAb discovery, it is expected
that more potent antibodies will be found that can be delivered by antibody gene transfer
approaches. These highly potent antibodies may offset the requirement for large serum
concentration levels of human IgG for prophylaxis or treatment. As DMAb technology
progresses alongside this improvement in mAb discovery, the clinical feasibility of DMAb
delivery will only increase.
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The public health impacts of DMAb technology use in humans could be
immense. With less dependence on the cold chain compared to purified protein and viral
stocks, DMAbs may have a substantial impact in locations where the electrical grid and
health care infrastructure lack stability. This benefit could have major importance during
infectious disease outbreaks, when rapid protection is desired but health care systems
are overwhelmed. From an economic standpoint, the savings in manufacturing costs (no
protein or viral purification) and health care infrastructure costs (no cold chain) suggest
that DMAb technology may have a favorable cost-effectiveness profile compared to
other mAb delivery and antibody gene transfer methods. Of course, these implications
are only important if efficacy is achieved in non-human primates and clinical trials; the
next steps of this technology, in addition to all that has been mentioned above, involve
determining the feasibility of DMAbs in larger animals and using those studies to inform
dosing and administration regimens in humans.
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CHAPTER 6 – Appendix
Table A1. Summary of antibody gene transfer studies targeting infectious
diseases.
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Table A1 (continued)

78

Figure A1. DNA plasmid-mediated antibody gene transfer
Traditional passive transfer requires the large-scale, expensive production of purified
mAbs and the intravenous infusion of those mAbs into hosts; thi 5s process generally
results in short-term duration of mAbs in the circulation, necessitating repeated infusions
for clinical benefit. DNA plasmid-mediated antibody gene transfer, or DMAb delivery,
involves the intramuscular injection of optimized antibody genes delivered by in vivo
electroporation (EP). Through this process, muscle cells become antibody-producing
factories that continuously secrete mAbs into the circulation.
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CHAPTER 7 – Publications
The following papers have been published in support of this dissertation, starting with
the most recently published work.
Rapid and long-term immunity elicited by DNA encoded antibody prophylaxis and
DNA vaccination against Chikungunya virus.
Muthumani K, Block P, Flingai S, Muruganantham N, Chaaithanya IK, Tingey C, Wise
M, Reuschel EL, Chung C, Muthumani A, Sarangan G, Srikanth P, Khan AS, Vijayachari
P, Sardesai NY, Kim JJ, Ugen KE, Weiner DB. J Infect Dis doi:10.1093/infdis/jiw111
(2016).
Abstract
Background. Vaccination and passive antibody therapies are critical for controlling
infectious diseases. Passive antibody administration has limitations including the
necessity for purification and the delivery of multiple injections required for efficacy.
Vaccination is associated with a lag phase before generation of immunity. Novel
approaches reported here utilize the benefits of both methods for the rapid generation of
effective immunity.
Methods. An antibody-based prophylaxis/therapy entailing the electroporation-mediated
delivery of synthetic plasmids, encoding biologically active anti-Chikungunya virus
envelope mAb (designated dMAb), was designed and evaluated for anti-viral efficacy as
well as for the ability to overcome shortcomings inherent with conventional active
vaccination by a novel passive immune-based strategy.
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Results. One intramuscular injection of the CHIKV-dMAb produced antibodies in vivo
more rapidly than active vaccination with a CHIKV-DNA vaccine. This dMAb neutralized
diverse CHIKV clinical isolates and protected mice from viral challenge. Combinations of
both afford rapid as well as long-lived protection.
Conclusions. We report that a DNA based dMAb strategy induces rapid protection
against an emerging viral infection, which can be combined with DNA vaccination
providing a uniquely both short term and long-term protection against this emerging
infectious disease. These studies have implications for pathogen treatment and control
strategies.

Protection

against

dengue

disease

by

synthetic

nucleic

acid

antibody

prophylaxis/immunotherapy.
Flingai S, Plummer EM, Patel A, Shresta S, Mendoza JM, Broderick KE, Sardesai NY,
Muthumani K, Weiner DB. Sci Rep 5, 12616 (2015).
Abstract
Dengue virus (DENV) is the most important mosquito-borne viral infection in humans. In
recent years, the number of cases and outbreaks has dramatically increased worldwide.
While vaccines are being developed, none are currently available that provide balanced
protection against all DENV serotypes. Advances in human antibody isolation have
uncovered DENV neutralizing antibodies (nAbs) that are capable of preventing infection
from multiple serotypes. Yet delivering monoclonal antibodies using conventional
methods is impractical due to high costs. Engineering novel methods of delivering
monoclonal antibodies could tip the scale in the fight against DENV. Here we
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demonstrate that simple intramuscular delivery by electroporation of synthetic DNA
plasmids engineered to express modified human nAbs against multiple DENV serotypes
confers

protection

against

DENV

disease

and

prevents

antibody-dependent

enhancement (ADE) of disease in mice. This synthetic nucleic acid antibody
prophylaxis/immunotherapy approach may have important applications in the fight
against infectious disease.

Synthetic DNA vaccines: improved vaccine potency by electroporation and codelivered genetic adjuvants.
Flingai S, Czerwonko M, Goodman J, Kudchodkar SB, Muthumani K, Weiner DB. Front
Immunol 4, 354 (2013).
Abstract
In recent years, DNA vaccines have undergone a number of technological
advancements that have incited renewed interest and heightened promise in the field.
Two such improvements are the use of genetically engineered cytokine adjuvants and
plasmid delivery via in vivo electroporation (EP), the latter of which has been shown to
increase antigen delivery by nearly 1000-fold compared to naked DNA plasmid delivery
alone. Both strategies, either separately or in combination, have been shown to augment
cellular and humoral immune responses in not only mice, but also in large animal
models. These promising results, coupled with recent clinical trials that have shown
enhanced immune responses in humans, highlight the bright prospects for DNA
vaccines to address many human diseases.
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Optimized and enhanced DNA plasmid vector based in vivo construction of a
neutralizing anti-HIV-1 envelope glycoprotein Fab.
Muthumani K, Flingai S, Wise M, Tingey C, Ugen KE, Weiner DB. Hum Vaccin
Immunother 9, 2253-62 (2013).
Abstract
Monoclonal antibody preparations have demonstrated considerable clinical utility in the
treatment of specific malignancies, as well as inflammatory and infectious diseases.
Antibodies are conventionally delivered by passive administration, typically requiring
costly large-scale laboratory development and production. Additional limitations include
the necessity for repeat administrations, and the length of in vivo potency. Therefore, the
development of methods to generate therapeutic antibodies and antibody like molecules
in vivo, distinct from an active antigen-based immunization strategy, would have
considerable clinical utility. In fact, adeno-associated viral (AAV) vector mediated
delivery of immunoglobulin genes with subsequent generation of functional antibodies
has recently been developed. As well, anon-viral vector mediated nucleic acid based
delivery technology could permit the generation of therapeutic/prophylactic antibodies in
vivo, obviating potential safety issues associated with viral vector based gene delivery.
This delivery strategy has limitations as well, mainly due to very low in vivo production
and expression of protein from the delivered gene. In the study reported here we have
constructed an "enhanced and optimized" DNA plasmid technology to generate
immunoglobulin heavy and light chains (i.e., Fab fragments) from an established
neutralizing anti-HIV envelope glycoprotein monoclonal antibody (VRC01). This
"enhanced" DNA (E-DNA) plasmid technology includes codon/RNA optimization, leader
83

sequence utilization, as well as targeted potentiation of delivery and expression of the
Fab immunoglobulin genes through use of "adaptive" in vivo electroporation. The results
demonstrate that delivery by this method of a single administration of the optimized Fab
expressing constructs resulted in generation of Fab molecules in mouse sera
possessing high antigen specific binding and HIV neutralization activity for at least 7 d
after injection, against diverse HIV isolates. Importantly, this delivery strategy resulted in
a rapid increase (i.e., in as little as 48 h) in Fab levels when compared with proteinbased immunization. The active generation of functional Fab molecules in vivo has
important conceptual and practical advantages over conventional ex vivo generation,
purification and passive delivery of biologically active antibodies. Further study of this
technique for the rapid generation and delivery of immunoglobulin and immunoglobulin
like molecules is highly relevant and timely.
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